Two Drugs Appear to Hold PromiseCBLI is developing for Commercialization Two Prospective Drugs that Appear to Hold Promise
Protectan CBLB 502 - modified protein of a microbe that protect cells from apoptosis, and which therefore have a broad spectrum of potential applications, including protection from exposure to radiation (whether as a result of military or terrorist action or as a result of a nuclear accident), as well as medical applications such as reducing cancer treatment side effects.
Curaxins CBLC102 - small molecule designed to kill tumor cells by simultaneously targeting two regulators of apoptosis. It can be effective against a number of malignancies, including renal cell carcinoma, soft-tissue sarcoma and hormone refractory prostate cancer. Curaxin CBLC102, enters Phase II human trials in patients with androgen-independent (hormone refractory) prostate cancer in July 2006.